

Original citation:

du Toit, E., Squire, S. B., Dunbar, R., Machekano, R., Madan, Jason, Beyers, N. and Naidoo, P.. (2015) Comparing multidrug-resistant tuberculosis patient costs under molecular diagnostic algorithms in South Africa. *The international journal of tuberculosis and lung disease*, 19 (8). pp. 960-968.

Permanent WRAP URL:

<http://wrap.warwick.ac.uk/85052>

Copyright and reuse:

The Warwick Research Archive Portal (WRAP) makes this work by researchers of the University of Warwick available open access under the following conditions. Copyright © and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable the material made available in WRAP has been checked for eligibility before being made available.

Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

Publisher's statement:

© IITLD 2015

A note on versions:

The version presented here may differ from the published version or, version of record, if you wish to cite this item you are advised to consult the publisher's version. Please see the 'permanent WRAP URL' above for details on accessing the published version and note that access may require a subscription.

For more information, please contact the WRAP Team at: wrap@warwick.ac.uk

1 **A comparison of multidrug-resistant tuberculosis patient costs under molecular**
2 **diagnostic algorithms in South Africa.**

3

4 **Authors:**

5 Elizabeth du Toit¹, S. Bertel Squire², Rory Dunbar¹, Rhoderick Machekano³, Jason Madan⁴, Nulda
6 Beyers¹, Pren Naidoo¹

7

8 **Affiliations:**

9

10 ¹Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and
11 Health Sciences, Stellenbosch University, South Africa

12 ²Liverpool School of Tropical Medicine, Liverpool, United Kingdom

13 ³Biostatistics Unit, Centre for Evidence Based Health Care, Faculty of Medicine and Health
14 Sciences, Stellenbosch University, South Africa

15 ⁴Warwick Medical School, University of Warwick, Coventry, United Kingdom

16

17 **Corresponding author:** Elizabeth du Toit, Desmond Tutu TB Centre, Department of Paediatrics
18 and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa,
19 Telephone: (+27) 219389114, Fax: (+27)21 9389719, Email: elizabethd@sun.ac.za

20

21 **Conflicts of interest:**

22 The authors declare that there are no conflicts of interest

23

24 **Author contributions:** EdT, SBS, NB and PN were involved in the study design, EdT, PN in the
25 data collection, EdT, RD, RM, JM in the data analysis, EdT, SBS, RD, RM, JM, NB, and PN in writing
26 the manuscript

27

28 **Running head:** MDR-TB patient costs

29 **Text word count:** 4039

30

31 **SUMMARY**

32

33 **Setting:** The study took place in Cape Town, South Africa from 2010-2013 as part of an
34 observational cohort in 10 primary health facilities.

35 **Study Aim:** A comparison of costs incurred by patients in MDRTBPlus line probe assay and Xpert
36 MTB/RIF-based diagnostic algorithms, from the onset of illness until multidrug-resistant
37 tuberculosis treatment initiation.

38 **Methods:** Eligible patients were identified from laboratory and facility records, interviewed **3-6**
39 **months after treatment initiation** and a cost questionnaire completed. Direct and indirect costs,
40 individual and household income, loss of individual income and change in household income
41 were recorded in local currency, adjusted to 2013 costs and converted to US\$.

42 **Results:** The median number of visits to initiation of multidrug-resistant tuberculosis treatment
43 was reduced from 20 to 7 ($p < 0.001$) and median costs from \$68.1 to \$38.3 ($p = 0.004$) in the
44 Xpert group. From the **onset of symptoms** to being interviewed, the proportion unemployed
45 increased from 39% to 73% in the LPA group ($p < 0.001$) and from 53% to 89% in the Xpert
46 group ($p < 0.001$). There was a decrease of 16% in median household income in the LPA group
47 and 13% in the Xpert group.

48 **Conclusion:** The introduction of an Xpert-based algorithm brought relief by decreasing the cost
49 incurred by patients, but the loss of employment and income persist. Patients require support to
50 mitigate this impact.

51

52

53 **Key words:** molecular diagnostic tests, patient costs, income loss, impact assessment.

54

55

56 **BACKGROUND**

57 *"TB is the child of poverty - and also its parent and provider" [Archbishop Desmond Tutu.]*

58
59 Tuberculosis (TB) disproportionately affects the poor(1) due to a complex interaction between
60 many factors, including, poor nutrition, overcrowded living or working conditions, and
61 concomitant disease, such as human immunodeficiency virus (HIV) infection(2,3). TB
62 perpetuates a cycle of poverty with affected families losing household income through disability
63 or death and confronting costs in diagnosing and treating the disease. TB also affects the most
64 economically viable, being among the top three causes of death for women aged 15 - 44 years(4).

65
66 TB patients incur significant costs from the onset of their illness until diagnosis, with costs, as a
67 percentage of household income, being higher for poor patients(5-9). Long delays exist between
68 the onset of TB symptoms and initiation of TB treatment, attributed to both the patient and the
69 health system(10,11). The longer this delay, the more likely a patient is to both transmit TB(12)
70 and to incur costs for transport, accessing healthcare, purchasing pharmaceuticals, and losing
71 work time and productivity.

72
73 Several systematic reviews report on diagnostic and treatment costs faced by TB patients. Costs
74 ranged widely between countries with one review reporting the largest costs being incurred for
75 hospitalization, medication, transportation and private healthcare(6). Ukwaja et al(13) report
76 mean diagnostic costs for patients in Africa ranging between 10.4% to 35% of mean annual
77 income and concluded that average diagnostic costs for TB were "catastrophic", **defined in**
78 **different studies as costs greater than 10% of monthly or annual household income, greater than**
79 **40% of non-subsistence household income, or the use of non-reversible coping strategies (5,14).**
80 **Patients in the lowest income bracket face the greatest risk of "catastrophic" costs(5).** Tanimura
81 et al(14) found that direct medical costs accounted on average for 20%, direct non-medical costs
82 for 20% and income loss for 60% of total cost for patients in low- and middle-income countries.
83 Pre-treatment costs accounted for half of total costs. **In Burkina Faso, 72% of patients were**
84 **found to have incurred direct medical costs during the pre-diagnostic phase(15).**

85
86 Those with multi-drug resistant (MDR) TB face an even greater economic burden, with low cure
87 rates and lengthy treatment of up to two years(16-18). Three studies reported by Tanimura et
88 al disaggregated the total costs for TB and MDR-TB patients and showed that costs were higher

89 for those with MDR-TB(14). In one of these studies pre-diagnostic costs for MDR-TB patients
90 were just over double that of TB patients(17). No studies from sub-Saharan Africa were found
91 pertaining specifically to MDR-TB patient diagnostic costs.

92
93 Implementation of Xpert MTB/RIF (Xpert) has reduced the time taken to diagnose MDR-TB(19)
94 and it is anticipated that patients will benefit economically through fewer pre-treatment
95 healthcare visits, and the potential for an earlier diagnosis to decrease morbidity and mortality.
96 It is important to ascertain the benefit which new technology affords to vulnerable groups(20).
97 This study compared costs incurred by patients in MDRTBPlus line probe assay (LPA) and Xpert-
98 based diagnostic algorithms, from the onset of **symptoms** until MDR-TB treatment initiation.

99

100 **METHODS**

101

102 **Setting:**

103

104 The study took place in a routine operational setting in Cape Town, South Africa. **The country has**
105 **high levels of poverty, with 56.8% of people living below the poverty line(21). Household**
106 **incomes show persistent disparities along racial lines, with average annual household income of**
107 **ZAR387,011 amongst “white” households compared to ZAR 69,632 amongst “black” households**
108 **and 48.7% of “black” households with annual household income <ZAR9,886(22). The**
109 **government has implemented a range of social protection measures to combat this, including**
110 **both conditional (child support and disability grants) and unconditional (pensions for men >65**
111 **and women >60-years old) cash transfers and the provision of free primary health services (23).**

112

113 Free TB diagnostic services were provided at 142 primary health-care (PHC) facilities in Cape
114 Town; 101 of these together with the dedicated TB-hospital offered free TB treatment. There
115 was a PHC facility within about a 5 km radius of all households. TB tests were done at a central
116 laboratory and results recorded in an electronic laboratory database.

117

118 In 2010, a smear, culture and LPA-based diagnostic algorithm was in place (Figure 1) with LPA
119 performed on culture isolates in high MDR-risk TB presumptive cases. From 2011 Xpert was
120 sequentially introduced into facilities, replacing smear microscopy for all presumptive TB cases
121 (Figure 1). In both algorithms, cases with a failing 1st line TB treatment regimen were evaluated

122 for MDR-TB through culture and LPA. We refer to patients diagnosed under these algorithms as
123 the LPA and Xpert groups respectively.

124
125 MDR-TB patients received standardised treatment regimens. At the start of data collection in
126 2010, doctors at the TB hospital reviewed case records and prescribed treatment but most
127 patients initiated treatment at PHC facilities. Since 2012 (mid-way through the study), doctors
128 could initiate MDR-TB treatment at PHC facilities without the need for prior review of case
129 records at the TB-hospital.

130

131 **Study Population:**

132

133 The study was part of an observational cohort in 10 high TB-burden PHC facilities selected from
134 a total of 29 that met the criteria of a TB caseload of >350 in 2009. **We sorted facilities from best
135 to worst performing based on new smear positive treatment outcomes and randomly selected
136 five facilities above and five below the median treatment success rate of 78%.**

137

138 Eligible patients diagnosed in either algorithm were >18-years of age, had been diagnosed with
139 rifampicin or rifampicin and isoniazid resistance from sputa tested in Cape Town between June
140 2010 and December 2012, and had received MDR-TB treatment at one of the 10 PHC facilities.
141 Patients with previous MDR-TB treatment were excluded, as their pathway to care may have
142 been different. Those with pre- or extensively drug-resistant TB or who had interrupted MDR-TB
143 treatment at the time of the scheduled interview were excluded. For infection control and safety
144 of the researchers, only patients who had been on MDR-TB treatment for at least 3 months and
145 were smear negative were interviewed.

146

147 **Data Sources and Collection:**

148

149 Patients diagnosed at selected facilities were identified from the electronic laboratory database;
150 those diagnosed elsewhere, but on treatment at selected facilities, were identified from facility
151 DR-TB paper registers and clinical records.

152

153 Trained professional nurses located patient folders, reviewed study eligibility and recorded
154 demographic, laboratory and clinical data, and the patients' healthcare visits on case report

155 forms. The clinical coordinator used this information to populate a timeline on a patient cost
156 questionnaire with the number and dates of visits. This was used to probe and clarify responses
157 provided by the patient during the interview.

158
159 **Three to six months after the start of treatment, one of two graduate social scientists** obtained
160 informed consent and conducted interviews with patients **at the PHC facility**, in their language of
161 choice. **A structured** cost questionnaire was completed detailing the patient's care-seeking visits
162 **from the reported onset of symptoms** to MDR-TB treatment **initiation**. This included time spent
163 at healthcare facilities, travel time and out of pocket payments. Employment status and
164 individual and household income were assessed **both prior to the onset of symptoms and at the**
165 **time of the interview**. The clinical coordinator checked the questionnaire and the text relating to
166 care seeking visits and transcribed data onto a coded spreadsheet.

167

168 **Costs Assessed:**

169

170 Direct costs comprised medical (for private practitioner consultation, diagnostic tests and
171 medication) and non-medical (travel for return trips to the healthcare provider) expenditure as
172 reported by patients. Money spent on food and expenditure incurred for persons accompanying
173 the patient were not assessed. Indirect costs comprised opportunity costs for patient time. The
174 number of healthcare visits was determined from the folder review and patient interview.
175 Patient time comprised time spent in a healthcare facility, 8 hours per day for hospitalized
176 patients, and time spent in travel to the healthcare facility. The cost per hour for patient time
177 was calculated for all patients using the hourly wage (ZAR11.17) of a municipal worker in Cape
178 Town in 2013(24). We decided to use a basic wage for all patients as it was difficult to calculate
179 an average hourly wage for the large percentage that were unemployed or self-employed and
180 worked variable hours. The implications of this method are addressed in the discussion.

181

182 **The total cost to the patient was calculated as the sum of direct and indirect costs.** All costs were
183 calculated in local currency (ZAR) for that year, adjusted to 2013 costs using the annual
184 consumer price index(25) and converted to US\$ based on average United Nations treasury
185 operational rates in 2013(26).

186

187 **Definitions:**

188

189 **Healthcare visit:** Any visit made to a pharmacy, private practitioner, traditional healer or
190 medical facility to seek care from the **reported onset of symptoms** with the current illness to
191 MDR-TB treatment initiation. This included directly observed therapy (DOT) visits for those on
192 1st-line TB treatment prior to MDR-TB treatment initiation; **non TB-related visits were excluded.**

193 **MDR-TB diagnostic time-point:** Defined as either **pre-treatment**, for a presumptive TB case
194 being concurrently evaluated for TB and drug resistance, or as **on 1st line TB treatment**, for a
195 case on a failing 1st-line TB regimen being evaluated for drug susceptibility.

196

197 **Data Management and Statistical analysis:**

198

199 Data from the case report forms and cost questionnaire were double entered into a Microsoft
200 SQL database, corrected and analyzed using STATA 12 (StataCorp). Some information on the
201 variables collected was incomplete and only reported data have been analysed. We compared
202 differences between the algorithms and between MDR-TB diagnostic time points. Categorical
203 data were summarized using proportions and compared using the chi-square test. Continuous
204 data were summarized using means and standard deviations or medians and interquartile
205 ranges. Continuous variables were assessed using either the two-sample t-test or Wilcoxon rank
206 sum test depending on the distribution of the variable.

207

208 Median as opposed to mean visits and costs are presented as the data were skewed and medians
209 are considered a more representative reflection of the sample. Mean values are presented as
210 supplementary information. We used a quantile regression model to assess the effect of potential
211 confounders such as age, gender, previous TB and HIV status on median visits and costs.

212

213 **Ethics:**

214

215 The Health Research Ethics Committee at Stellenbosch University (IRB0005239)(N10/09/308)
216 and Ethics Advisory Group at The International Union Against Tuberculosis and Lung Disease
217 (59/10) approved the study. The City Health Directorate, Western Cape Health Department and
218 National Health Laboratory Service granted permission to use routine health data for which a
219 waiver of informed consent was granted. All study participants provided informed consent for
220 interviews.

221

222 **RESULTS**

223

224 **Demographic and clinical characteristics:**

225

226 Of the 226 eligible patients, 153 were interviewed and 73 were excluded (Figure 2). **Excluded**
227 **patients did not differ** significantly in gender ($p=0.344$), age ($p=0.561$), HIV status ($p=0.893$),
228 previous TB treatment ($p=0.101$), or MDR-TB diagnostic time-point ($p=0.471$) **from those**
229 **included**.

230

231 Demographic and clinical data are presented in Table 1 for the 89 patients in the LPA and 64 in
232 the Xpert groups. There were no significant differences in sex, age, HIV status, and previous TB
233 treatment between the groups. The majority of patients were diagnosed at the pre-treatment
234 diagnostic time-point in both groups. The median household size was smaller in the LPA than the
235 Xpert group ($p=0.001$).

236

237 **Healthcare visits from the start of illness to MDR-TB treatment initiation:**

238

239 The median number of health visits to MDR-TB treatment initiation was reduced from 20 in the
240 LPA group to 7 in the Xpert group ($p<0.001$) (Table 2). For those diagnosed at the pre-treatment
241 diagnostic time-point, the median number of visits was reduced from 16 in the LPA group to 6 in
242 the Xpert group ($p<0.001$). There were no significant differences between the groups for those
243 diagnosed whilst on 1st-line TB treatment ($p=0.375$).

244

245 In the quantile regression model (Table 3), age, gender, HIV status and previous TB were not
246 significantly associated with the number of visits. When adjusting for these potential
247 confounders, there were 12 (95% CI 3 to 21, $p=0.009$) fewer visits in the Xpert group. Cases
248 diagnosed at the pre-treatment diagnostic time-point had 10 fewer visits (95% CI 4 to 15,
249 $p>0.001$) in the Xpert group. For those diagnosed whilst on 1st line TB treatment, there was no
250 significant difference in the number of visits between the groups ($p=0.624$).

251

252 The proportion of patients who visited a private practitioner was similar, with 30% in the LPA
253 and 31% in the Xpert group ($p=0.905$). The proportion hospitalized at some point prior to MDR-

254 TB treatment initiation was also similar with 19% in both groups ($p=0.957$). A higher proportion
255 attended a healthcare facility or a community site for DOT relating to their 1st line TB regimen in
256 the LPA group (69%) than in the Xpert group (39%) ($p<0.001$).

257

258 **Cost to the patient:**

259

260 The total median cost to the patient from the start of the illness to MDR-TB treatment initiation
261 was reduced from \$68.1 (IQR 32.0 to 142.0) in the LPA group to \$38.3 (IQR 14.1 to 79.3) in the
262 Xpert group ($p=0.004$)(Table 4). Median direct costs were \$6.7 (IQR \$1.1 to \$28.2) in the LPA
263 group and \$4.4 (IQR 0.0 to \$22.2) in the Xpert group ($p=0.321$). Median indirect costs were
264 reduced from \$40.0 (IQR \$20.4 to \$105.9) in the LPA group to \$22.1 (IQR \$11.0 to \$54.5) in the
265 Xpert group ($p=0.003$).

266

267 All patients incurred indirect costs, but only 34 patients in the LPA group and 22 in the Xpert
268 group incurred direct medical costs with medians of \$22.9 (IQR \$17.2 to \$28.9) and \$22.0 (IQR
269 \$15.7 to \$26.0) respectively. Direct transport cost were incurred by 66 patients in the LPA group
270 and 41 in the Xpert group with medians of \$5.3 (IQR 2.7 to 8.1) and \$4.6 (IQR 1.6 to 10.3)
271 respectively.

272

273 For those diagnosed at the pre-treatment diagnostic time-point, the total median cost to the
274 patient was reduced from \$49.8 (IQR 23.7 to 96.4) in the LPA group to \$29.0 (IQR 12.5 to 57.6)
275 in the Xpert group ($p=0.004$). For those diagnosed whilst on 1st line TB treatment the total
276 median cost to the patient was \$167.6 (IQR 105.1 to 273.2) in the LPA group compared to \$179.4
277 (IQR 65.8 to 228.7) in the Xpert group ($p=0.531$).

278

279 In the quantile regression model (Table 3), gender, HIV status and previous TB were not
280 significantly associated with costs. When adjusting for these potential confounders, there was a
281 reduction of \$35.4 (95% CI 6.1 to 64.7, $p=0.018$) in median costs in the Xpert group. Cases
282 diagnosed at the pre-treatment diagnostic time-point had a reduction of \$23.5 (95% CI \$1.7 to
283 \$45.2, $p>0.035$) in the Xpert group. There was no significant difference in costs between the
284 groups ($p=0.583$) for those diagnosed whilst on 1st line TB treatment. Costs for those diagnosed
285 on 1st line TB treatment were \$102.6 higher ($p<0.001$) in LPA group and \$147.9 higher in the
286 Xpert group compared to those diagnosed pre-treatment in each group.

287

288 **Change in employment status:**

289

290 From the start of their illness to being interviewed the proportion unemployed increased from
291 39% to 73% in the LPA group ($p<0.001$) and from 53% to 89% in the Xpert group ($p<0.001$)
292 (Table 5). In the LPA group 36% lost employment after the start of their illness compared to
293 27% in the Xpert group ($p=0.222$); 94% in both groups reported this to be directly attributable
294 to having contracted MDR-TB. Both patients who stopped schooling or tertiary education in the
295 LPA group and 6 of the 7 in the Xpert group reported this as attributable to MDR-TB.

296

297 **Change in individual and household income:**

298

299 In the LPA group 58% earned an income from employment prior to MDR-TB illness compared to
300 36% in the Xpert group. Of those earning an income, 67% in the LPA group and 65% in the Xpert
301 group lost income between the start of their illness and MDR-TB treatment initiation (Table 5).

302

303 Prior to their illness 20 (22%) patients in the LPA group and 17 (27%) in the Xpert group
304 received money from a social grant, of which 1 in the LPA group and 5 in the Xpert group
305 comprised a temporary or permanent disability grant (Table 5). At the time of the interview an
306 additional 36 (40%) in the LPA group and 14 (22%) in the Xpert group ($p=0.016$) received
307 temporary disability grants, linked to their illness.

308

309 In both groups 97% knew or could estimate their monthly household income with 38% in the
310 LPA group and 27% in the Xpert group losing >10% of monthly household income between the
311 start of their illness and time of the interview (Table 5). Overall there was a 16% decrease in
312 median household income in the LPA group compared to 13% in the Xpert group.

313

314 **DISCUSSION**

315

316 This study compared costs incurred by MDR-TB patients in an existing LPA-based diagnostic
317 algorithm to that in a newly introduced Xpert-based algorithm from the reported onset of
318 symptoms to MDR-TB treatment initiation. The number of health- visits (and thus costs) was
319 expected to decrease in the Xpert-based algorithm for two reasons: firstly, Xpert provided a

320 quicker DST result than LPA (median <1 day compared to 24 days to a result being available in
321 the laboratory(19)), thus fewer patients would be started on 1st line TB treatment whilst
322 awaiting a DST result. Secondly, all presumptive TB cases would be simultaneously screened for
323 TB and drug susceptibility in the Xpert group; in comparison, those at low risk of MDR-TB in the
324 LPA group were only evaluated for drug susceptibility when 1st line TB treatment failed (usually
325 after 2-3 months of treatment). An algorithm where all presumptive cases are tested for drug
326 resistance, irrespective of the test used, will decrease the number of **pre-treatment visits** by
327 earlier identification of drug resistance for many patients.

328
329 **The introduction of the Xpert-based algorithm** decreased the number of pre-treatment
330 healthcare visits from a median of 20 in the LPA group to 7 in the Xpert group. However, the
331 number of visits remains high, especially for patients diagnosed whilst on 1st-line TB treatment.
332 A large contributor to this was DOT visits whilst awaiting a DST result. Visits to private
333 practitioners (similar in both algorithms) and to health centers not offering TB treatment
334 increased the number of pre-treatment visits **as patients often made several visits, were not**
335 **appropriately tested and had to eventually be referred for MDR-TB tests and or treatment.**

336
337 There was a significant decrease in median costs for patients in the Xpert (\$38.3) compared to
338 the LPA group (\$68.1). As **direct medical costs were similar in both groups (all related to private**
339 **sector care as public sector services are free) and travel costs were low**, this was largely
340 attributable to indirect costs related to time spent in travel and at the healthcare facility. Other
341 TB costing studies have also found higher indirect than direct costs (17,18).

342
343 **Improved health system efficiencies with the Xpert-based algorithm can help to further reduce**
344 **indirect costs. To achieve** this, healthcare professionals need to adhere to the testing algorithm
345 and health delivery issues such leaking sputum containers, broken fax machines, and mislaid
346 results need to be minimized to eliminate unnecessary pre-treatment visits.

347
348 Other studies have found income loss to be the largest financial burden faced by patients
349 contracting TB(14). We found a high proportion of patients, in both algorithms, who lost income
350 as a result of employment loss due to their illness, highlighting the devastating impact MDR-TB
351 can have on a patient's livelihood, irrespective of the speed at which they are diagnosed. Studies
352 are needed to ascertain if people regain employment, once they have commenced or completed

353 treatment, however with the poor treatment outcomes for MDR-TB (27) this is likely to be low.
354 There was a marked loss of monthly household income in both groups. “Catastrophic” costs (14)
355 were experienced by 38% in the LPA group and 27% in the Xpert group who lost >10% of
356 monthly household income.

357
358 When estimating costs, different approaches may influence the cost estimate. In this study
359 indirect costs for patient’s time were calculated for all patients based on a basic municipal
360 workers wage. This may have overestimated indirect costs for those unemployed, although this
361 effect may be counter-balanced, as the study did not cost unpaid work in the household and the
362 cost to the unemployed who lost time that could have been used to seek new employment.

363
364 There are also alternative methods of calculating indirect costs – we have used the traditional
365 human capital method, which assumes a loss equivalent to the production that could have
366 occurred in the time foregone, using hourly wages to value this production(28). Alternative
367 methods, such as the friction cost approach(29) assume some reorganization to minimize
368 disruption (e.g. individuals substituting leisure time for paid or unpaid work). Our approach may
369 therefore overstate indirect costs by not accounting for such flexibility, although it is not possible
370 to quantify the impact of this.

371

372 **Strengths and Limitations:**

373

374 As patients were interviewed 3 to 6 months after the start of MDR-TB treatment, recall bias may
375 have influenced findings. A strength of our study was that we were able to triangulate
376 visit data from patient interviews with clinical records which is likely to have reduced reporting
377 bias.

378

379 However, the study had limitations. Firstly, this was an observational study conducted in routine
380 operational conditions. Temporal changes such as the full decentralisation of MDR-TB treatment
381 may have contributed to the findings. Secondly, the patients sampled were not representative of
382 all MDR-TB patients. Untreated patients were not included. To reduce the risk of infection to
383 researchers, only patients who had been on MDR-TB treatment for at least 3 months and had
384 smear-converted were interviewed. Patients who were lost to follow-up, which may have been
385 influenced by the high cost of illness, or had failed to smear convert were not included. Healthier

386 people were thus more likely to be interviewed, which may have underestimated costs, but this
387 is unlikely to have been different between the two algorithms.

388
389 **Thirdly, we did not assess coping strategies that patients may have resorted to such as the sale of**
390 **assets and borrowing.** Lastly, we have not assessed visits or costs based on clinic performance as
391 the clinic ranking changed each year and the number of patients was too small. The study
392 included **the early phase of Xpert implementation**, which may have increased the median
393 number of pre-treatment visits in the Xpert group as staff became familiar with the new
394 algorithm and new practices were entrenched.

395

396 **Implications of Study Findings:**

397

398 Given the high loss of employment attributable to their having developed MDR-TB, many of
399 these patients and their households are in need of financial support. There have been
400 international calls by the World Health Organisation and International Labour Office for
401 countries to invest in social protection mechanisms such as income replacement and social
402 support for those affected by illness(30).

403

404 **Although disability grants (monthly value \$129.2) are available to support MDR-TB patients and**
405 **offer a measure of income replacement, access to these was** poor with fewer patients receiving a
406 disability grant at the time of the interview in the Xpert (22%) compared to the LPA group
407 (40%). This may reflect the time it takes to process a grant, with this not yet having taken place
408 for those diagnosed in the Xpert-based algorithm. **Expedited access to disability grants is**
409 **required: the provision of unconditional disability grants could be considered for diseases such**
410 **as MDR-TB as the means-testing process (undertaken by a doctor) contributes to delay. On a**
411 **positive note, the low direct medical costs incurred by patients bare testimony to the social**
412 **protection offered by free public health services in South Africa.**

413

414 **CONCLUSION**

415

416 **Assessing** the economic relief to the patient and their household is important in understanding
417 the impact of new molecular TB diagnostics. This study has shown that the introduction of an
418 Xpert-based algorithm brought relief by decreasing the costs incurred by patients, mostly **by**

419 reducing the number of visits to treatment initiation. Improved health service efficiencies can
420 help further reduce costs.

421
422 The link between TB and poverty is strong (1,31). In our setting, even though MDR-TB diagnosis
423 and treatment are free and easily accessible, the economic impact of MDR-TB was large, with
424 many patients losing employment and individual and household income. It is important for
425 health planners to be cognizant of the fact that irrespective of how quickly treatment is initiated
426 with a rapid MDR-TB test, a high number of patients will be vulnerable to the effects of increased
427 poverty. Efforts need to be made to mitigate this to break the poverty-illness cycle.

429 **Acknowledgements**

430 This research was supported by a United States Agency for International Development (USAID)
431 Cooperative Agreement (TREAT TB – Agreement No. GHN-A-00-08-00004-00). The contents are
432 the responsibility of the authors and do not necessarily reflect the views of USAID.

433 The assistance of the National Health Laboratory Services, Cape Town Health Directorate and
434 Western Cape Provincial Department of Health is acknowledged. We are grateful to Edina
435 Sinanovic, Health Economics Unit, University of Cape Town, for her advice.

436

437 **References**

- 438 1. Muniyandi M, Ramachandran R. Socioeconomic inequalities of tuberculosis in India. *Expert Opin*
439 *Pharmacother*. Informa UK Ltd London, UK; 2008 Jul 21;9(10):1623–8.
- 440 2. World Health Organisation. Addressing Poverty in TB Control: Options for National TB Control
441 Programmes. 2005 p. 3–78.
- 442 3. Lönnroth K, Jaramillo E, Williams BG, Dye C, Raviglione M. Drivers of tuberculosis epidemics: the
443 role of risk factors and social determinants. *Soc Sci Med*. 2009 Jun;68(12):2240–6.
- 444 4. World Health Organisation. Tuberculosis Fact sheet N°104. World Health Organization; 2014.
- 445 5. Laokri S, Dramaix-Wilmet M, Kassa F, Anagonou S, Dujardin B. Assessing the economic burden of
446 illness for tuberculosis patients in Benin: determinants and consequences of catastrophic health
447 expenditures and inequities. *Trop Med Int Health*. 2014 Oct;19(10):1249–58.
- 448 6. Barter DM, Agboola SO, Murray MB, Bärnighausen T. Tuberculosis and poverty: the contribution of
449 patient costs in sub-Saharan Africa--a systematic review. *BMC Public Health*. 2012 Jan;12:980.
- 450 7. Croft RA, Croft RP. Expenditure and loss of income incurred by tuberculosis patients before
451 reaching effective treatment in Bangladesh [Notes from the Field]. *Int J Tuberc Lung Dis*.
452 International Union Against Tuberculosis and Lung Disease; 1998;2(3):3.
- 453 8. Kamolratanakul P, Sawert H, Kongsin S, Lertmaharit S, Sriwongsa J, Na-Songkhla S, et al. Economic
454 impact of tuberculosis at the household level. *Int J Tuberc Lung Dis*. 1999 Jul;3(7):596–602.
- 455 9. Kemp JR, Mann G, Simwaka BN, Salaniponi FM, Squire SB. Can Malawi's poor afford free
456 tuberculosis services? Patient and household costs associated with a tuberculosis diagnosis in
457 Lilongwe. *Bull World Health Organ*. World Health Organization; 2007;85(8):580–5.
- 458 10. Sreeramareddy CT, Panduru K V, Menten J, Van den Ende J. Time delays in diagnosis of pulmonary
459 tuberculosis: a systematic review of literature. *BMC Infect Dis*. 2009 Jan;9:91.
- 460 11. Narasimooloo R, Ross a. Delay in commencing treatment for MDR TB at a specialised TB treatment
461 centre in KwaZulu-Natal. *S Afr Med J*. 2012 Jun;102(6 Pt 2):360–2.
- 462 12. Dowdy DW, Chaisson RE, Maartens G, Corbett EL, Dorman SE. Impact of enhanced tuberculosis
463 diagnosis in South Africa: a mathematical model of expanded culture and drug susc1. Dowdy DW,
464 Chaisson RE, Maartens G, Corbett EL, Dorman SE (2008) Impact of enhanced tuberculosis
465 diagnosis in South Africa: a mathematical m. *Proc Natl Acad Sci U S A*. 2008 Aug
466 12;105(32):11293–8.
- 467 13. Ukwaja KN, Modebe O, Igwenyi C, Alobu I. The economic burden of tuberculosis care for patients
468 and households in Africa: a systematic review. *Int J Tuberc Lung Dis*. 2012 Jun;16(6):733–9.
- 469 14. Tanimura T, Jaramillo E, Weil D, Raviglione M, Lönnroth K. Financial burden for tuberculosis
470 patients in low- and middle-income countries: a systematic review. *Eur Respir J*. 2014 Feb 20;1–
471 13.
- 472 15. Laokri S, Drabo MK, Weil O, Kafando B, Dembélé SM, Dujardin B. Patients are paying too much for
473 tuberculosis: a direct cost-burden evaluation in Burkina Faso. *PLoS One*. 2013 Jan;8(2):e56752.

- 474 16. World Health Organisation. Global Tuberculosis Report. 2012 p. 1–82.
- 475 17. Pichenda K, Nakamura K, Morita A, Kizuki M, Seino K, Takano T. Non-hospital DOT and early
476 diagnosis of tuberculosis reduce. *Int J Tuberc Lung Dis.* 2012;16(December 2011):828–34.
- 477 18. Rouzier V a, Oxlade O, Verduga R, Gresely L, Menzies D. Patient and family costs associated with
478 tuberculosis, including multidrug-resistant tuberculosis, in Ecuador. *Int J Tuberc Lung Dis.* 2010
479 Oct;14(10):1316–22.
- 480 19. Naidoo P, du Toit E, Dunbar R, Lombard C, Caldwell J, Detjen A, et al. A Comparison of Multidrug-
481 Resistant Tuberculosis Treatment Commencement Times in MDRTBPlus Line Probe Assay and
482 Xpert® MTB/RIF-Based Algorithms in a Routine Operational Setting in Cape Town. *PLoS One.*
483 2014 Jan;9(7):e103328.
- 484 20. Mann G, Squire SB, Bissell K, Eliseev P, Toit E Du, Hesselning A, et al. Beyond accuracy : creating a
485 comprehensive evidence base for tuberculosis diagnostic tools. *Int J Tuberc Lung Dis.*
486 2010;14(12):1518–24.
- 487 21. Statistics South Africa. Statistical release Living Conditions of Households in SA 2008/2009. 2011.
- 488 22. Statistics South Africa. Income and Expenditure of Households 2010 / 2011. 2011;
- 489 23. Pauw K, Mncube L. Expanding the Social Security Net in South Africa : Opportunities, Challenges
490 and Constraints. 2007.
- 491 24. Mywage.co.za/South Africa - Minimum Wages for Farm Workers, Fiorestry, Security Guards,
492 Domestic Workers in South Africa 2013 [Internet]. [cited 2014 Jun 5]. Available from:
493 <http://m.mywage.co.za/main/salary/minimum-wages>
- 494 25. Bennett M, Voges A. Statistical release Consumer Price Index. 2014 p. 2–10.
- 495 26. United Nations treasury Operational Rates of Exchange [Internet]. [cited 2014 May 27]. Available
496 from:
497 [http://treasury.un.org/operationalrates/Details.aspx?code=ZAR¤cy=South+Africa+Rand&c](http://treasury.un.org/operationalrates/Details.aspx?code=ZAR¤cy=South+Africa+Rand&country=South+Africa)
498 [ountry=South+Africa](http://treasury.un.org/operationalrates/Details.aspx?code=ZAR¤cy=South+Africa+Rand&country=South+Africa)
- 499 27. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, et al. Multidrug resistant
500 pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data
501 meta-analysis of 9,153 patients. *PLoS Med.* 2012 Jan;9(8):e1001300.
- 502 28. Hodgson T. Costs of Illness in Cost-Effectiveness Analysis : a review of the methodology.
503 *Pharmacoeconomics.* 1994;6(6):536–52.
- 504 29. Koopmanschap MA, Rutten FFH, van Ineveld BM, van Roijen L. The friction cost method for
505 measuring indirect costs of disease. *J Health Econ.* 1995 Jun;14(2):171–89.
- 506 30. International Labour office, World Health Organisation. A joint Crisis Initiative of the UN Chief
507 Executives Board for Co-ordination on the Social Protection Floor. Geneva; 2009 p. 2–19.
- 508 31. World Health Organisation. The role of Tuberculosis (TB) in poverty eradication. 2011 p. 5–7.
- 509

510

511 **Table 1: Demographic, Socioeconomic and Clinical Characteristics of Study Patients**

Variable	LPA Group (n=89)	Xpert Group (n=64)	p-value
Sex, Female (number, %)	44 (49%)	27 (42%)	p=0.375
Mean Age, years	36.8	35.3	p=0.300
SD (Range)	10.7 (19-70)	9.7 (19-63)	
HIV-positive (number, %)	57 (64%)	34 (53%)	p=0.175
Previous TB treatment (number, %)	45 (51%)	30 (47%)	p=0.653
MDR-TB diagnostic time-point: Pre-treatment (number, %)	74 (83%)	55 (86%)	p=0.644
Highest Education level attained ¹ (number, %)			p = 0.525
• No education	2 (2%)	0 (0%)	
• Primary school education (Grade 1-Grade 7)	29 (33%)	15 (24%)	
• Some high school education (Gr 8- Grade 11)	44 (49%)	36 (57%)	
• Completed high school education (Grade 12)	13 (15%)	7 (11%)	
• Tertiary education	1 (1%)	5 (8%)	
Median number of people in household	3	4	p=0.003
IQR	2-4	3-5.5	
Median number of dependents	2	1	p=0.235
IQR	1-3	0-2.5	

538 ¹Education level was missing for one patient in the Xpert group.

539 Abbreviations: LPA= MDRTBPlus line probe assay; Xpert = Xpert MTB/RIF; SD= Standard Deviation; HIV=Human
 540 Immunodeficiency Virus; TB=Tuberculosis; MDR-TB= Multidrug Resistant Tuberculosis; IQR= Interquartile Range

541

542

Table 2: Median Number of Healthcare Visits in the LPA and Xpert Groups

	Median	IQR	Min-Max	p-value
LPA Group - all patients (n=89)	20	10-44	2-171	p<0.001
Xpert Group - all patients (n=64)	7	4-23	2-184	
LPA Group - pre-treatment (n=74)	16	7-28	2-164	p<0.001
Xpert Group -pre-treatment (n=55)	6	4-12	2-73	
LPA Group - on 1 st line TB treatment (n=15)	77	48-126	25-171	p=0.373
Xpert Group - on 1 st line TB treatment (n=9)	51	46-77	19-184	

558 *The table shows unadjusted data. Healthcare visits include all visits to both the public and private health sector. Visits*
 559 *for directly observed therapy (DOT) are included for patients on a 1st line TB regimen, either whilst awaiting drug*
 560 *susceptibility test results or for those who were not evaluated when diagnosed with TB. Only 1.4% of visits in the LPA*
 561 *group and 3.2% in the Xpert group were to the private sector.*
 562 *Abbreviations: LPA = MDRTBPlus line probe assay; Xpert = Xpert MTB/RIF; TB = Tuberculosis; IQR = Interquartile*
 563 *Range; Min-Max = Minimum - Maximum*
 564 *Data on mean visits are presented in supplemental information.*
 565
 566

567 **Table 3: Quantile Regression Model Outputs for Number of Healthcare Visits and Patient Costs**

Variable	Coefficient	Standard Error	p-value	95% Confidence ⁵⁶⁸
Adjusted Data for Number of Healthcare Visits – All patients				
Xpert Group	-11.9	4.5	0.009	-20.8 to -3.1
Gender	5.4	4.5	0.224	-3.4 to 14.3
HIV status	-0.9	4.5	0.843	-9.8 to 8.0
Age	-0.1	0.2	0.742	-0.5 to 0.4
Previous TB	-0.4	4.4	0.921	-9.2 to 8.3
Constant	20.8	9.2	0.026	2.5 to 39.1
Adjusted Data for Number of Healthcare Visits – Patients at Pre-treatment Diagnostic Time				
Xpert Group	-9.6	2.7	0.001	-14.9 to -4.2
Gender	2.3	2.7	0.401	-3.1 to 7.6
HIV status	-0.1	2.7	0.979	-5.4 to 5.3
Age	-0.1	0.1	0.524	-0.4 to 0.2
Previous TB	1.8	2.7	0.509	-3.5 to 7.1
Constant	17.2	5.8	0.004	5.6 to 28.7
Adjusted Data for Number of Healthcare Visits – Patients at Treatment Diagnostic Time Point				
Xpert Group	-13.4	26.8	0.624	-69.8 to 43.0
Gender	16.6	24.7	0.510	-35.3 to 68.5
HIV status	15.7	25.4	0.545	-37.7 to 69.2
Age	-0.9	1.1	0.405	-3.3 to 1.4
Previous TB	57.9	35.2	0.117	-16.0 to 131.8
Constant	88.7	42.2	0.050	0.1 to 177.3
Adjusted Patient Cost Data (\$) – All patients				
Xpert Group	-35.4	14.8	0.018	-64.7 to -6.1
Gender	9.4	14.7	0.524	-19.7 to 38.5
Previous TB	-15.2	14.6	0.298	-44.0 to 13.6
HIV status	-0.7	15.0	0.962	-30.4 to 28.9
Constant	74.3	16.5	<0.001	41.7 to 107.0
Adjusted Patient Cost Data (\$) – Patients at Pre-treatment Diagnostic Time Point				
Xpert Group	-23.5	11.0	0.035	-45.2 to -1.7
Gender	7.3	10.9	0.506	-14.3 to 28.8
Previous TB	1.9	10.8	0.865	-19.6 to 23.3
HIV status	-1.7	11.1	0.880	-23.6 to 20.3
Constant	48.8	12.9	<0.001	23.2 to 74.3
Adjusted Patient Cost Data (\$)– Patients at Treatment Diagnostic Time Point				
Xpert Group	-55.4	99.1	0.583	-262.8 to 152.1
Gender	48.8	90.3	0.595	-140.3 to 237.9
Previous TB	114.1	130.2	0.392	-158.4 to 386.5
HIV status	3.4	92.7	0.972	-190.7 to 197.4
Constant	121.2	86.8	0.179	-60.5 to 302.9
Adjusted Cost Comparison at the different Diagnostic Time Points in the LPA-based Algorithm				
Pre-treatment	102.6	25.0	<0.001	52.8 to 152.4
Constant	69.2	21.3	0.002	26.8 to 111.6
Adjusted Cost Comparison at the different Diagnostic Time Points in the Xpert-based				
Pre-treatment	147.9	24.3	<0.001	99.3 to 196.5
Constant	14.6	15.5	0.349	-16.4 to 45.6

Table 4: Median Patients Costs in the LPA and Xpert Groups

	n	Median Direct Costs (\$) (IQR)				Median Indirect Costs (\$) (IQR)				Median Total Cost to Patient (IQR) p-value	
		Transport Costs	Medical Costs	Direct Costs p-value		Cost of Transport Time	Cost of Time in Health Facility	Indirect Costs p-value			
LPA Group – all patients	89	3.4 (0-6.9)	0 (0-18.1)	6.7 (1.1-28.2)	p=0.321	12.3 (6.2-29.6)	23.7 (11.7-64.4)	40.0 (20.4-105.9)	p=0.003	68.1 (32.0-142.0)	p=0.004
Xpert Group – all patients	64	1.5 (0-6.5)	0 (0-16.0)	4.4 (0.0-22.2)		4.6 (2.6-14.3)	13.4 (8.2-39.0)	22.1 (11.0-54.5)		38.3 (14.1-79.3)	
LPA Group – Pre-treatment	74	3.2 (0-6.9)	0 (0-18.1)	6.5 (1.1-25.9)	p=0.345	9.9 (5.8-23.2)	19.9 (8.9-46.1)	33.7 (17.5-87.1)	p=0.005	49.8 (23.7-96.4)	p=0.004
Xpert Group – Pre-treatment	55	1.5 (0-6.5)	0 (0-15.7)	4.2 (0.0-20.3)		4.0 (2.5-9.9)	12.1 (7.3-30.3)	17.3 (10.9-46.7)		29.0 (12.5-57.6)	
LPA Group - on 1 st line TB treatment	15	4.5 (0-6.2)	0 (0-24.1)	27.5 (0.0-30.0)	p=0.928	54.8 (30.1-91.2)	86.4 (31.9-117.0)	164.7 (76.1-234.5)	p=0.297	167.6 (105.1-273.2)	p= 0.531
Xpert Group - on 1 st line TB treatment	9	3.4 (0-21.7)	0 (0-22.9)	4.6 (0.0-44.6)		25.4 (21.6-46.9)	37.0 (19.1-155.6)	61.3 (46.7-202.4)		179.4 (65.8-228.7)	

570 *Costs and time associated with seeking help were calculated from the onset of illness to MDR-TB treatment initiation in South African Rands, adjusted to 2013 values*
571 *based on the consumer price index, and converted to US\$ at a rate of 9.75 (average United Nations Treasury operational rates in 2013). The total cost to the patient is*
572 *the sum of the direct and indirect costs.*

573 *The table shows data for all patients in both groups. However, only 67 patients in the LPA group and 45 in the Xpert group incurred direct costs with medians of \$20.5*
574 *(IQR 5.0 to 30.3) and \$12.4 (IQR \$3.4 to \$30.4) respectively. Direct medical costs were incurred by 34 patients in the LPA group and 22 in the Xpert group with median*
575 *costs of \$22.9 (IQR \$17.2 to \$28.9) and \$22.0 (IQR \$15.7 to \$26.0) respectively. Direct transport cost were incurred by 66 patients in the LPA group and 41 in the Xpert*
576 *group with median costs of \$5.3 (IQR 2.7 -8.1) and \$4.6 (IQR 1.6-10.3) respectively.*

577 *Abbreviations: LPA = MDRTBplus line probe assay; Xpert = Xpert MTB/RIF; IQR = Interquartile Range*

578 *Mean costs are presented as supplemental information.*

579 **Table 5: A Comparison of Employment Status and Individual and Household Income**

580

	LPA Group (n = 89)	Xpert Group (n = 64)	p-value
Number unemployed prior to illness (%)	35 (39%)	34 (53%)	p=0.091
Number unemployed at time of interview (%)	65 (73%)	57 (89%)	p=0.015
Median monthly income from salary prior to illness amongst employed (\$) (IQR) ¹	228.9 (153.4-330.9)	265.6 (194.7-303.6)	p=0.628
Median loss of monthly income from salary from start of illness to time of interview amongst employed (\$) (IQR)	224.4 (144.2-320.5)	251.9 (160.3-303.6)	p=0.719
Of those receiving a grant pre-illness: number receiving money from a disability grant (%)	1 (1%)	5 (8%)	-
Additional number receiving money from a disability grant at time of interview (not including those above) ²	36 (40%)	14 (22%)	p=0.016
Number receiving money from any grant pre-illness (as % of total)	20 (22%)	17 (27%)	p=0.560
Median monthly grant amount (\$) pre-illness (IQR)	32.4 (30.9-80.5)	60.7 (30.4-137.3)	p=0.298
Median monthly additional grant amount at the time of the interview (\$) ³ (IQR)	123.6 (121.4-125.9)	126.6 (123.1-130.1)	p=0.593
Median monthly household income from all sources prior to illness (\$) (IQR)	259.3 (130.5-427.9) n = 86	356.6 (130.5-618.2) n = 62	p=0.057
Median monthly household income from all sources at time of interview (\$) (IQR)	216.8 (123.6-343.5) n = 86	308.9 (130.1-471.6) n = 60	p=0.043
Number of households losing monthly household income after becoming ill (reported at time of interview) (%) ⁴	33 (38%) n = 86	17 (27%) n = 62	p=0.165

581 *Where data was incomplete or refers to a subset, we specify the denominator as: n = number reported.*

582 *All income or loss thereof was recorded in South African Rands, adjusted to 2013 values based on CPI, and converted to*
 583 *US\$ at a rate of 9.75 (average United Nations Treasury operational rates in 2013).*

584 ¹*52 patients in the LPA and 23 patients in the Xpert group earned an income from their occupation prior to the start of*
 585 *illness and 52 in the LPA and 22 in the Xpert groups were able to report their income.*

586 ²*19 previously employed patients in the LPA group and 4 in the Xpert group received a monthly disability grant of*
 587 *\$129.2*

588 ³*Additional grants were all temporary disability grants linked to their illness.*

589 ⁴*All households losing income lost >10% of monthly household income.*

590 *Abbreviations: LPA = MDRTBplus line probe assay; Xpert = Xpert MTB/RIF; IQR = Interquartile Range; MDR-TB =*
 591 *Multidrug Resistant Tuberculosis.*

592
 593

Figure 1: Testing in the LPA and Xpert-based TB Diagnostic Algorithms




Figure 2: Study Population

